Please assess the completion status of the following clinical trial:

Trial Title: CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a diagnosis of type 2 diabetes~* Body mass index (BMI) \>=22 to \<=45 kg/m2, at screening~* Patients must be taking a stable dosage of metformin as monotherapy at screening~* Patients must have a HbA1c between \>=7% and \<=9.5% at Week 2~* Patients must have a fasting plasma glucose (FPG) \<=270 mg/dL (15 mmol/L) at Week -2~Exclusion Criteria:~* Patients having prior exposure or known contraindication or suspected hypersensitivity to JNJ-28431754, glimepiride, or metformin~* History of diabetic ketoacidosis or type 1 diabetes mellitus~* History of pancreas or beta-cell transplantation~* History of active proliferative diabetic retinopathy~* History of hereditary glucose-galactose malabsorption or primary renal glucosuria~* Renal disease requiring treatment with immunosuppressive therapy within the past 12 months before screening or a history of dialysis or renal transplant~* Taken thiazolidinedione therapy in the past 16 weeks before screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Glimepiride (Type: ACTIVE_COMPARATOR): Each patient will receive glimepiride, at protocol-specified doses, once daily in combination with protocol-specified doses of metformin for 104 weeks.
- Canagliflozin 100 mg (Type: EXPERIMENTAL): Each patient will receive 100 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.
- Canagliflozin 300 mg (Type: EXPERIMENTAL): Each volunteer will receive 300 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).